Jupiter Topco LLC Purchases Shares of 6,494,571 Equillium, Inc. $EQ

by · The Cerbat Gem

Jupiter Topco LLC purchased a new stake in Equillium, Inc. (NASDAQ:EQ – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,494,571 shares of the company’s stock, valued at approximately $20,685,000. Jupiter Topco LLC owned 10.27% of Equillium at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EQ. Dimensional Fund Advisors LP acquired a new position in shares of Equillium in the first quarter worth approximately $31,000. Virtu Financial LLC increased its position in Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after purchasing an additional 13,591 shares during the period. Millennium Management LLC acquired a new stake in Equillium during the 3rd quarter valued at approximately $35,000. OMERS ADMINISTRATION Corp acquired a new stake in Equillium during the 1st quarter valued at approximately $100,000. Finally, Royal Bank of Canada bought a new position in Equillium during the 4th quarter worth approximately $124,000. 27.05% of the stock is currently owned by institutional investors.

Insider Transactions at Equillium

In other news, insider Stephen Connelly sold 200,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $3.16, for a total transaction of $632,000.00. Following the completion of the sale, the insider directly owned 793,000 shares of the company’s stock, valued at $2,505,880. The trade was a 20.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Christine Zedelmayer sold 14,584 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $2.93, for a total transaction of $42,731.12. Following the completion of the sale, the chief operating officer owned 62,586 shares in the company, valued at $183,376.98. This represents a 18.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 245,559 shares of company stock valued at $765,798 over the last quarter. Corporate insiders own 17.84% of the company’s stock.

Equillium Stock Down 2.4%

Shares of EQ opened at $2.39 on Friday. Equillium, Inc. has a 12-month low of $0.76 and a 12-month high of $3.54. The business’s fifty day moving average is $2.55 and its 200 day moving average is $2.29. The stock has a market cap of $151.55 million, a P/E ratio of -11.95 and a beta of 1.82.

Equillium (NASDAQ:EQ – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. On average, analysts expect that Equillium, Inc. will post -0.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EQ. Roth Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Equillium in a research note on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Equillium in a research note on Wednesday, June 24th. Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $1.00 to $6.00 in a report on Thursday, May 28th. Piper Sandler started coverage on shares of Equillium in a research report on Monday, July 13th. They set an “overweight” rating on the stock. Finally, Stifel Nicolaus set a $5.00 price target on Equillium in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Equillium currently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

Check Out Our Latest Analysis on EQ

Equillium Profile

(Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.

Read More

Want to see what other hedge funds are holding EQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Equillium, Inc. (NASDAQ:EQ – Free Report).